For research use only. Not for use in humans.

Anti-EphA2 (MEDI-547)

Synonyms: MEDI-547

Anti-EphA2 (MEDI-547) is a fully human IgG1 monoclonal antibody that is used for targeting EphA2. It selectively binds to cells expressing the EphA2 receptor. MW: 145.12 KD.

Anti-EphA2 (MEDI-547)

Quality Control

Batch: A251101 Purity: 99% Protein concentration: 5.34mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation Ephrin receptor Others
NVP-BHG712 17 C-Raf,c-Src,c-Abl
ALW II-41-27 7
Sitravatinib (MGCD516) 10 DDR2,Axl,VEGFR3 (FLT4)
NVP-BHG712 isomer 0
AWL-II-38.3 0
Ehp-inhibitor-1 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Anti-EphA2 (MEDI-547) is a fully human IgG1 monoclonal antibody that is used for targeting EphA2. It selectively binds to cells expressing the EphA2 receptor. MW: 145.12 KD.

Product Details

Molecular Weight 145.12 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06186401 RECRUITING Drug: Cyclophosphamide (non-investigational)|Drug: Fludarabi EGFR Gene Mutation; Glioblastoma; MGMT-Unmethylated Glioblastoma; Recurrent Glioblastoma Hideho Okada, MD, PhD 2024-04-30 PHASE1
NCT00796055 TERMINATED Drug: MEDI-547 Cancer MedImmune LLC 2009-08 PHASE1

(data from https://clinicaltrials.gov, updated on 2026-08-13)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.